Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...
Eli Lilly: Steep Pullback, Still Compelling Here
LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...
'Nuclear Option'?: Eli Lilly Taps Big Law Firms in Federal Drug Pricing Dispute
The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...
The Motley Fool on MSN3d
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Eli Lilly now ranks as the largest drugmaker in the world based ... Much of Lilly's recent dismal stock performance ...
Eli Lilly and Company: Lilly announces changes on board of directors
Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...
GlobalData on MSN5d
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
Healthy Returns: Eli Lilly's cholesterol pill impresses in mid-stage trial
The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
Eli Lilly and China-based biotech Laekna team on obesity drug
Earlier on Wednesday, Laekna, “a global biotech company focused on novel drug development for metabolic and cancer diseases,” accoding to its ...
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...